Date: 2013-11-05
Type of information:
phase: 1
Announcement:
Company: Swedish Orphan Biovitrum (Sobi) (Sweden)
Product: SOBI002
Action mechanism: SOBI002 is a small biologic molecule based on the Affibody® platform that works as a potent and selective inhibitor of complement protein C5, a key protein in human immunological and inflammatory processes and central to a number of important diseases.
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On November 5, 2013, Swedish Orphan Biovitrum (Sobi) has announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial. The study will evaluate single and repeated doses of SOBI002 administered subcutaneously and intravenously in healthy volunteers. Sobi expects to be able to commence the clinical trial during the first quarter 2014.
